Neurocrine survey shows fewer work, school disruptions after Ingrezza treatment
NBIX•Neurocrine Biosciences released survey findings showing fewer work and school disruptions among adults with tardive dyskinesia taking Ingrezza. A separate post-hoc analysis found patient-reported improvements in physical functioning and socio-emotional well-being; the findings will be presented Nov. 5-8, 2026.
1. Findings on Ingrezza
Neurocrine Biosciences released survey findings showing fewer work and school disruptions among adults with tardive dyskinesia taking Ingrezza. A separate post-hoc analysis of the Phase 4 KINECT-PRO study showed patient-reported improvements in physical functioning and socio-emotional well-being. The findings will be presented at the Neuroscience Education Institute Fall Congress, Nov. 5-8, 2026, in Colorado Springs, Colorado.
